New pill shows promise for severe hair loss, but trial cut short
NCT ID NCT05496426
First seen May 30, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This study tested an oral drug called KL130008 in 114 adults with severe alopecia areata, a condition causing significant scalp hair loss. The goal was to see if the drug could regrow hair to at least 80% coverage. However, the trial was terminated early, so the full results are not available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangzhou, 510080, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KL130008 capsule
What this could lead to
If successful, this could point toward a new oral treatment option for people with severe alopecia areata, potentially regrowing significant scalp hair.
What could go wrong
The trial was terminated early, so results are limited. It is a Phase 2 study, meaning it is still early and may not confirm effectiveness or safety in larger groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.